23rd Jun 2026 20:20
Thalia Therapeutics PLC - biotechnology company developing innovative RNA therapeutics - Pretax loss is flat at GBP1.2 million in 2025 when compared to the year prior. Loss per share is 0.17 pence versus 0.31p the year before, revenue is little changed at GBP7,264 versus GBP7,282. Research and development costs fall to GBP214,120 from GBP390,387 and general and administration costs rise to GBP1.0 million from GBP837,996. "Alongside our internally developed assets, we are in advanced stages of potentially adding a clinical-stage microRNA therapeutic asset to the company's portfolio. If successful, this, combined with the continued advancement of Nuvec, our dual-targeting siRNA programme, is the first step in creating a differentiated and valuable RNA therapeutics company," says Chief Executive David Solomon. Read More
